Keywords: Teva, Share repurchase, Financial outlook
Teva to make massive share buy-back; expects $22 billion sales for 2011
Article | 22 December 2011
Israel-based generic drugs giant Teva Pharmaceutical Industries (Nasdaq: TEVA) has announced it plans to repurchase a massive $3 billion of its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
